NSG 5240 Advanced Pharmacology – Final
Practice Exam Study Guide
Question Set Overview
Total Questions: 70+
Format: Multiple Choice with Verified Answers and Detailed Rationales
Core Domains Covered: Pharmacokinetics, Cardiovascular
Pharmacology, Endocrine/Metabolic Agents, Neuro/Psychotropic Drugs,
Anti-infectives, and Prescribing Regulations.
SECTION 1: PHARMACOKINETICS &
PHARMACODYNAMICS
1. A patient with liver cirrhosis has reduced metabolism of a drug
that normally undergoes extensive first-pass effect. How will this
affect the oral dose of the drug?
A. Increased first-pass metabolism
B. Decreased bioavailability
C. Significantly increased bioavailability
D. No change in drug levels
Answer: C. Significantly increased bioavailability
Rationale: The first-pass effect occurs in the liver. Liver impairment means
less drug is metabolized before reaching systemic circulation, leading to
higher bioavailability and potential toxicity.
,2. A drug has a half-life of 12 hours. How many hours will it take to
reach steady state?
A. 24 hours
B. 36 hours
C. 48 hours
D. 60 hours
Answer: D. 60 hours
*Rationale: Steady state is achieved after approximately 4-5 half-lives. 5 ×
12 hours = 60 hours.*
3. Which route of administration bypasses the first-pass effect?
A. Oral
B. Sublingual
C. Rectal
D. Both B and C
Answer: D. Both B and C
Rationale: Sublingual and rectal administration allow absorption directly into
systemic circulation, partially or fully avoiding portal circulation and first-
pass metabolism in the liver.
4. A patient with chronic kidney disease requires a medication
adjustment. Which pharmacokinetic process is most significantly
altered?
A. Absorption
B. Distribution
C. Metabolism
D. Excretion
Answer: D. Excretion
Rationale: The kidneys handle elimination for most drugs. A reduced
glomerular filtration rate impairs clearance and raises toxicity risk, requiring
dose adjustments based on creatinine clearance.
, 5. A drug has a volume of distribution of 500 L. What does this
primarily indicate?
A. The drug is highly protein-bound
B. The drug is confined to vascular space
C. The drug extensively distributes into tissues
D. The drug has a short half-life
Answer: C. The drug extensively distributes into tissues
Rationale: A high Vd (greater than total body water of ~42 L) suggests the
drug is leaving the plasma extensively and binding to tissues. This is
common for lipophilic drugs like digoxin and amiodarone.
6. Bioavailability of an intravenously (IV) administered drug is:
A. 0%
B. Less than 50%
C. 100%
D. Variable based on lipophilicity
Answer: C. 100%
Rationale: IV administration bypasses absorption barriers, delivering 100% of
the dose directly into systemic circulation.
7. A patient with hepatic cirrhosis is prescribed a prodrug. The
nurse practitioner anticipates:
A. Enhanced therapeutic effect
B. Reduced conversion to active metabolite
C. Increased first-pass metabolism
D. No change in drug activity
Answer: B. Reduced conversion to active metabolite
Rationale: A prodrug requires liver metabolism to become active. Liver
impairment reduces this conversion, potentially leading to therapeutic
failure.
Practice Exam Study Guide
Question Set Overview
Total Questions: 70+
Format: Multiple Choice with Verified Answers and Detailed Rationales
Core Domains Covered: Pharmacokinetics, Cardiovascular
Pharmacology, Endocrine/Metabolic Agents, Neuro/Psychotropic Drugs,
Anti-infectives, and Prescribing Regulations.
SECTION 1: PHARMACOKINETICS &
PHARMACODYNAMICS
1. A patient with liver cirrhosis has reduced metabolism of a drug
that normally undergoes extensive first-pass effect. How will this
affect the oral dose of the drug?
A. Increased first-pass metabolism
B. Decreased bioavailability
C. Significantly increased bioavailability
D. No change in drug levels
Answer: C. Significantly increased bioavailability
Rationale: The first-pass effect occurs in the liver. Liver impairment means
less drug is metabolized before reaching systemic circulation, leading to
higher bioavailability and potential toxicity.
,2. A drug has a half-life of 12 hours. How many hours will it take to
reach steady state?
A. 24 hours
B. 36 hours
C. 48 hours
D. 60 hours
Answer: D. 60 hours
*Rationale: Steady state is achieved after approximately 4-5 half-lives. 5 ×
12 hours = 60 hours.*
3. Which route of administration bypasses the first-pass effect?
A. Oral
B. Sublingual
C. Rectal
D. Both B and C
Answer: D. Both B and C
Rationale: Sublingual and rectal administration allow absorption directly into
systemic circulation, partially or fully avoiding portal circulation and first-
pass metabolism in the liver.
4. A patient with chronic kidney disease requires a medication
adjustment. Which pharmacokinetic process is most significantly
altered?
A. Absorption
B. Distribution
C. Metabolism
D. Excretion
Answer: D. Excretion
Rationale: The kidneys handle elimination for most drugs. A reduced
glomerular filtration rate impairs clearance and raises toxicity risk, requiring
dose adjustments based on creatinine clearance.
, 5. A drug has a volume of distribution of 500 L. What does this
primarily indicate?
A. The drug is highly protein-bound
B. The drug is confined to vascular space
C. The drug extensively distributes into tissues
D. The drug has a short half-life
Answer: C. The drug extensively distributes into tissues
Rationale: A high Vd (greater than total body water of ~42 L) suggests the
drug is leaving the plasma extensively and binding to tissues. This is
common for lipophilic drugs like digoxin and amiodarone.
6. Bioavailability of an intravenously (IV) administered drug is:
A. 0%
B. Less than 50%
C. 100%
D. Variable based on lipophilicity
Answer: C. 100%
Rationale: IV administration bypasses absorption barriers, delivering 100% of
the dose directly into systemic circulation.
7. A patient with hepatic cirrhosis is prescribed a prodrug. The
nurse practitioner anticipates:
A. Enhanced therapeutic effect
B. Reduced conversion to active metabolite
C. Increased first-pass metabolism
D. No change in drug activity
Answer: B. Reduced conversion to active metabolite
Rationale: A prodrug requires liver metabolism to become active. Liver
impairment reduces this conversion, potentially leading to therapeutic
failure.
